Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anemia of Chronic Disease Clear all
Completed Phase 3 Interventional Results available

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

NCT01295710
View directory record Official record
Conditions
GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
Interventions
US-ATG-F, Placebo
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

NCT00077597
View directory record Official record
Conditions
Anemia
Interventions
epoetin, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
Davis, California • Lakewood, Colorado • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

NCT05745883
View directory record Official record
Conditions
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
Interventions
DISC-0974, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Lone Tree, Colorado • DeLand, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 15, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00020969
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
arsenic trioxide
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
8
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

NCT00045305
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 15, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

NCT02075463
View directory record Official record
Conditions
Anemia, Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Azusa, California • Glendale, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Decitabine in Treating Patients With Myelodysplastic Syndrome

NCT00003361
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
decitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Not applicable Interventional

MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS)

NCT03556657
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
Music Therapy
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

NCT02243306
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 15, 2026, 1:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

NCT00343785
View directory record Official record
Conditions
Aplastic Anemia
Interventions
cyclophosphamide, anti-thymocyte globulin, cyclosporine, allogeneic bone marrow transplantation, methotrexate, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 15, 2026, 1:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

NCT00540995
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions
busulfan, etoposide, intensity-modulated radiation therapy, allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, tomotherapy
Drug · Radiation · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Not applicable Interventional

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

NCT00005893
View directory record Official record
Conditions
Neutropenia, Sickle Cell Anemia, Thalassemia Major, Red-Cell Aplasia, Pure
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, Bone marrow transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

NCT02879305
View directory record Official record
Conditions
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions
Daprodustat, rhEPO, Placebo, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
126
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 15, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

NCT00593554
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
Interventions
Total Body Irradiation, Thiotepa, Fludarabine, Rabbit ATG, Palifermin
Radiation · Drug · Biological
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

NCT00005797
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, Cyclophosphamide, VP-16, Fractionated Total Body Irradiation (FTBI)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 55 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

NCT00064090
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytarabine, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

NCT01587924
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Paragould, Arizona • Tempe, Arizona • Pine Bluff, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 15, 2026, 1:16 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

NCT00317226
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose (FCM)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

NCT00255710
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D for Sickle Cell Disease

NCT01331148
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 15, 2026, 1:16 AM EDT
Recruiting Not applicable Interventional

Predictors of Pain in Sickle Cell Disease

NCT06139510
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
Quantitative sensory testing
Other
Lead sponsor
Duke University
Other
Eligibility
15 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 1:16 AM EDT